Compare INDI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | DBVT |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 769.4M |
| IPO Year | N/A | N/A |
| Metric | INDI | DBVT |
|---|---|---|
| Price | $3.62 | $19.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.25 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 2.9M | 763.5K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,396,000.00 | $5,502,000.00 |
| Revenue This Year | $1.91 | $1,768.71 |
| Revenue Next Year | $30.15 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $2.93 |
| 52 Week High | $6.05 | $26.19 |
| Indicator | INDI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 57.63 |
| Support Level | $3.59 | $18.46 |
| Resistance Level | $3.95 | $22.89 |
| Average True Range (ATR) | 0.22 | 1.65 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 5.21 | 30.39 |
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.